ViroGates ASOCSE:VIRO -1.92%48 PS Ratio is 9.40 as of Jul. 11, 2026, which is 43% below its 10-year median of 16.55. GuruFocus rates OCSE:VIRO with a GF Score™ of 48/100 and a GF Value™ of kr6.74 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 803 Medical Devices & Instruments companies, ViroGates AS ranks worse than 83.44% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ViroGates AS's share price is kr10.20.
ViroGates AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.09. Hence, ViroGates AS's PS Ratio for today is 9.40.
The historical rank and industry rank for ViroGates AS's PS Ratio or its related term are showing as below:
OCSE:VIRO'
s PS Ratio Range Over the Past 10 Years
Min: 2.76 Med: 16.55 Max: 124.05
Current: 9.4
During the past 10 years, ViroGates AS's highest PS Ratio was 124.05. The lowest was 2.76. And the median was 16.55.
OCSE:VIRO's PS Ratio is ranked worse than 83.44% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 2.92
vs OCSE:VIRO: 9.40
ViroGates AS revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of ViroGates AS was 9.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -37.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -8.70% per year.
During the past 10 years, ViroGates AS's highest 3-Year average Revenue per Share Growth Rate was 76.20% per year. The lowest was -37.10% per year. And the median was 16.10% per year.
Back to Basics: PS Ratio
ViroGates AS (OCSE:VIRO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ViroGates AS PS Ratio Related Terms
ViroGates AS PS Ratio Historical Data
* Premium members only.
The historical data trend for ViroGates AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ViroGates AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where ViroGates AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ViroGates AS's PS Ratio for today is calculated as
ViroGates AS's Share Price of today is kr10.20. ViroGates AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ViroGates AS (OCSE:VIRO) has a PS Ratio of 9.40 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ViroGates AS and its competitors. This is 43% below median its historical median of 16.55. Over the past decade, ViroGates AS's PS Ratio has ranged from 2.76 to 124.05. According to the industry distribution chart, ViroGates AS ranks #670 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 83.4%.
Is ViroGates AS's PS Ratio too high?
ViroGates AS's current PS Ratio of 9.40 is 43% below median its 10-year median of 16.55. Over the past 10 years, this metric has ranged from a low of 2.76 to a high of 124.05. The Medical Devices & Instruments industry median PS Ratio is 2.92. ViroGates AS's value of 9.40 is 221.9% above this industry median. Based on the distribution chart, ViroGates AS ranks #670 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #670 out of 803 companies for PS Ratio. This places ViroGates AS in the lower half of its industry. The industry median PS Ratio is 2.92. ViroGates AS's value of 9.40 is 221.9% above this benchmark. Historically, ViroGates AS's own PS Ratio has ranged from 2.76 to 124.05 over the past decade. While the company's 10-year median is 16.55 vs. the industry median of 2.92, ViroGates AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.92, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current PS Ratio of 9.40 is 221.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current PS Ratio is 9.40, which is 43% below median its own 10-year median of 16.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.74, compared to a current price of kr10.20 — trading 51.3% above its estimated fair value. The current PS Ratio is 9.40, which is 43% below median its 10-year median of 16.55 and 221.9% above the Medical Devices & Instruments industry median of 2.92. ViroGates AS's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current PS Ratio is 9.40 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr10.20 is trading 51.3% above its estimated GF Value™ of kr6.74.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
PS Ratio: 9.40 (43% below median its 10-year median of 16.55)
GF Value™: kr6.74 vs. price of kr10.20 (51.3% above fair value)
Industry Position: 221.9% above the Medical Devices & Instruments median (#670 of 803)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
48GF Score
Get the complete analysis for OCSE:VIRO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
